Rationale and study design for the first precision medicine randomized placebo-controlled trial in the 16p11.2 deletion syndrome.
Rationale and study design for the first precision medicine randomized placebo-controlled trial in the 16p11.2 deletion syndrome. Expert Rev Neurother. 2026 Jun; 26(6):597-607.